Efficacy of GDP regimen for relapsed/refractory B-NHL (Phase II)

Efficacy of GDP regimen for relapsed/refractory B-NHL (Phase II) - GDP-P2(Jikei)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018291

Enrollment

Registered

2015-07-13

Start date

2014-11-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant lymphoma

Interventions

GDP regimen

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pathological diagnosis of B-NHL 2) Age: 20-74 3) Performance status(ECOG): 0-2 4) Recognition of relapse by CT-scan, or refractory to previous chemotherapy 5) Previous chemotherapeutic regimen: over 1 regimen 6) No history of administration of platinum 7) No CNS involvement of B-NHL 8) Have measurable lesions of B-NHL 9) Informed consent by patient

Exclusion criteria

Exclusion criteria: 1) Uncontrolable diabetes mellitus by insulin therapy 2) Uncontrolable hypertension. Coronary disease, cardiomyopathy, cardiac failure, arhythmia that needs drug therapy. 3) HBs-Ag, HCV-Ab, HIV-Ab: positive 4) Interstitial pneumonia, pulmonary fibrosis 5) Severe infection 6) Double cancer in active 7) Pregnancy, possibility of pregnancy, in breast-feeding 8) Psyciatric disease 9) Continuous systemic administration of steroid

Design outcomes

Primary

Measure	Time frame
Overall response rate	—

Countries

Japan

Contacts

Public ContactYutaro Kamiyama

The Jikei university school of medicine Oncology and hematology

stasia@jikei.ac.jp+81-3-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026